Is Vertex Pharmaceuticals Heading to $600?
Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy few years. The biotech company, known for its leadership in the cystic fibrosis (CF) treatment market, has proven its ability to broaden into other areas -- and win. The company gained approval for blood disorders treatment, Casgevy, and later for non-opioid pain drug, Journavx. And Vertex expanded its CF leadership with a new approval in that area, too.
Just recently, the company delivered more good news to investors: Povetacicept, its candidate for kidney disease IgA nephropathy, met its goals, and the company aims to submit it to regulators by the end of the month.
Considering the good news, is Vertex heading to $600? Let's find out.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€374.90
1.490%
The stock is an absolute favorite of our community with 47 Buy predictions and no Sell predictions.
With a target price of 461 € there is a positive potential of 22.97% for Vertex Pharmaceuticals Inc. compared to the current price of 374.9 €.
